Center for Advanced Cellular Therapeutics to Rise on Penn Medicine Campus The University of Pennsylvania reached an important milestone in its alliance with Novartis as it unveiled plans for the construction of a first-of-its-kind Center for Advanced Cellular Therapeutics on the Penn Medicine campus. [University of Pennsylvania] Press Release Cancer Research UK, Cancer Research Technology and Asterias Biotherapeutics Partner to Trial Immunotherapy Vaccine for Lung Cancer Cancer Research UK and Cancer Research Technology have reached an agreement with Asterias Biotherapeutics, Inc. to take forward Asterias’ novel immunotherapy treatment AST-VAC2 into clinical trials in subjects with non-small cell lung cancer. [Asterias Biotherapeutics, Inc.] Press Release Merck KGaA Discontinues Clinical Development Program of Tecemotide as a Monotherapy in Stage III Non-Small Cell Lung Cancer Merck KGaA announced that its biopharmaceutical division will discontinue the clinical development program of its investigational MUC1 antigen-specific cancer immunotherapy tecemotide as a monotherapy in Stage III non-small cell lung cancer. [Merck KGaA] Press Release Initiation of Phase III IMPALA Study with Immunotherapy MGN1703 in Colorectal Cancer MOLOGEN AG has enrolled the first patient in the international IMPALA study. Primary objective of the Phase III pivotal trial is to prove that a switch maintenance therapy with the cancer immunotherapy MGN1703 leads to an increased overall survival in patients with metastatic colorectal carcinoma. [MOLOGEN AG] Press Release Bone Therapeutics Receives Clearance for ALLOB® Phase II Trial in Spinal Fusion Bone Therapeutics announced that it has received clearance from the Competent Authorities and Central Ethics Committee in Belgium for a Phase II proof-of-concept study to assess safety and efficacy of its allogeneic osteoblastic cell therapy product ALLOB® in spinal fusion procedures for degenerative lumbar disc disease. [Bone Therapeutics] Press Release Clinical Trial to Test Safety of Stem Cell-Derived Therapy for Type 1 Diabetes Researchers at the University of California, San Diego School of Medicine, in partnership with ViaCyte, Inc. have launched the first-ever human Phase I/II clinical trial of a stem cell-derived therapy for patients with Type 1 diabetes. [University of California, San Diego] Press Release BerGenBio Granted Platform Patent – CellSelectâ„¢ Platform also Described in Peer-Reviewed Journal BerGenBio AS announced that the United States Patent and Trademark Office has issued United States Patent 8,735,064 covering a method for creating and identifying functional interference RNA molecules. [BerGenBio AS (MarketWatch, Inc.)] Press Release Advaxis Provides a Clinical Development Update for Its Immunotherapy, ADXS-HPV, for the Treatment of Cervical Cancer Advaxis, Inc. announced the completion of an End-of-Phase II Meeting with the United States Food and Drug Administration, for its lead Lm-LLO cancer immunotherapy, ADXS-HPV, for the treatment of recurrent cervical cancer in women. [Advaxis, Inc.] Press Release Tory Williams Combats Controversy Surrounding Stem Cell Therapy with New Book Mary Ann Liebert, Inc. announced the launch of first time hard cover title Inevitable Collision: The Inspiring Story that Brought Stem Cell Research to Conservative America, in an effort to bring awareness to the growing conversation and debate surrounding stem cell research and regenerative medicine. [Mary Ann Liebert, Inc. (EurekAlert)] Press Release |